A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
HanchorBio’s HCB301 is among the latest industry projects beginning first-in-human trials.
Two years after being snubbed by GSK, Ideaya shows the promise of MAT2A inhibition.
The implosion of Skyscraper-06 has a direct impact on at least two other TIGIT players.
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.
Skyscraper-06 blows up spectacularly, and that’s bad news for Skyscraper-01.
A three-way race is on to determine which Car-T therapy Gilead will take into pivotal trials.